现有与二代γ干扰素释放试验诊断结核病的临床效用:观察性队列研究
该前瞻性队列研究纳入英国低发病率地区845例疑似结核成人,评价现有及二代IGRA的诊断准确性。
要点
- 现有商业IGRA(T-SPOT.TB和QFT-GIT)诊断活动性结核准确性不足。
- 低发病率地区二代IGRA或可辅助快速排除疑似结核。
核心结论
- 现有商业IGRA对疑似结核的诊断评估准确性不足。
- 二代IGRA在低发病率地区可能具有足够高的灵敏度和低阴性似然比,有助于快速排除结核。
研究设计与样本
- 前瞻性队列研究,在英国常规二级医疗中纳入疑似结核成人。
- 1060例成人入组,845例纳入分析,363例最终诊断为结核。
- 基线检测现有商业IGRA(T-SPOT.TB和QFT-GIT)及二代IGRA,随访6-12个月确立最终诊断。
临床怎么用
- 在低发病率地区,现有商业IGRA不宜单独用于疑似结核的诊断评估。
- 二代IGRA的高灵敏度和低阴性似然比可能有助于快速排除结核,但需结合临床综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical utility of interferon-γ release assays (IGRAs) for diagnosis of active tuberculosis is unclear, although they are commonly used in countries with a low incidence of tuberculosis. We aimed to resolve this clinical uncertainty by determining the accuracy and utility of commercially available and second-generation IGRAs in the diagnostic assessment of suspected tuberculosis in a low-incidence setting. METHODS: We did a prospective cohort study of adults with suspected tuberculosis in routine secondary care in England. Patients were tested for Mycobacterium tuberculosis infection at baseline with commercially available (T-SPOT.TB and QuantiFERON-TB Gold In-Tube [QFT-GIT]) and second-generation (incorporating novel M tuberculosis antigens) IGRAs and followed up for 6-12 months to establish definitive diagnoses. Sensitivity, specificity, positive and negative likelihood ratios, and predictive values of the tests were determined. FINDINGS: Of the 1060 adults enrolled in the study, 845 were included in the analyses and 363 were diagnosed with tuberculosis. Sensitivity of T-SPOT.TB for all tuberculosis diagnosis, including culture-confirmed and highly probable cases, was 81·4% (95% CI 76·6-85·3), which was higher than QFT-GIT (67·3% [62·0-72·1]). Second-generation IGRAs had a sensitivity of 94·0% (90·0-96·4) for culture-confirmed tuberculosis and 89·2% (85·2-92·2) when including highly probable tuberculosis, giving a negative likelihood ratio for all tuberculosis cases of 0·13 (95% CI 0·10-0·19). Specificity ranged from 86·2% (95% CI 82·3-89·4) for T-SPOT.TB to 80·0% (75·6-83·8) for second-generation IGRAs. INTERPRETATION: Commercially available IGRAs do not have sufficient accuracy for diagnostic evaluation of suspected tuberculosis. Second-generation tests, however, might have sufficiently high sensitivity, low negative likelihood ratio, and correspondingly high negative predictive value in low-incidence settings to facilitate prompt rule-out of tuberculosis. FUNDING: National Institute for Health Research.
引用
- Whitworth HS, Badhan A, Boakye AA, et al. Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study. Lancet Infect Dis. 2019. PMID: 30655049. doi:10.1016/S1473-3099(18)30613-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。